FDA Panel Votes 'No' on Tivozanib for Renal Cancer
The FDA’s Oncologic Drugs Advisory Committee has voted 13 to 1 against AVEO's drug tivozanib for the treatment of patients with metastatic renal cell carcinoma.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news